Abstracts tagged "polychondritis and tocilizumab"

Abstract Number: 2036 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices
Mattia Baldini¹, Patrizia Aiello¹, Mirta Tiraboschi¹, Maria Grazia Sabbadini² and Elena Baldissera¹, ¹Internal Medicine and Clinical Immunology, Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy, ²Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milano, Italy
Background/Purpose: The inflammatory milieu in affected tissues from Relapsing Polychondritis (RP) is rich in TNF-α, IL-1-β and IL-6. Cytokine-targeted biologic therapies has therefore been proposed…
Abstract Number: 1923 • 2012 ACR/ARHP Annual Meeting
Biologics in Relapsing Polychondritis: A Single Center Case-Series
Guillaume Moulis¹, Laurent Sailler², Grégory Pugnet³, Leonardo Astudillo² and Philippe Arlet¹, ¹Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ³Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France
Background/Purpose: First-line treatment for relapsing polychondritis (RP) is costicosteroids (CS). Dapsone and methotrexate have been proposed as second-line therapies. Only few reports have been published…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].